Published Online: January 14, 2015. doi:10.1001/jamapsychiatry.2014.2412.
Study concept and design: Hampton, Alexander, Budnitz.
Acquisition, analysis, or interpretation of data: Hampton, Daubresse, Chang, Budnitz.
Drafting of the manuscript: Hampton.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Hampton, Daubresse, Chang.
Administrative, technical, or material support: All authors.
Study supervision: Alexander, Budnitz.
Conflict of Interest Disclosures: Dr Alexander is an ad hoc member of the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee, serves as a paid consultant to IMS Health, and serves on an IMS Health scientific advisory board. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. No other disclosures were reported.
Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Additional Contributions: The following contributed to data collection and adverse drug event case review: Joel Friedman, BS, Herman Burney, BS, Mary Cowhig, MHA, Thomas Schroeder, MS, and Ray Colucci, RN (Consumer Products Safety Commission); and Kathleen Rose, RN, and Kelly Weidenbach, DrPH (Centers for Disease Control and Prevention). Messrs Friedman, Burney, Schroeder, and Colucci and Ms Cowhig’s work on adverse drug event data collection and case review was funded by the Centers for Disease Control and Prevention.